Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Recommendations for antibiotic selection for severe nosocomial infections.

16 Dec, 2021 | 09:40h | UTC

Recommendations for antibiotic selection for severe nosocomial infections – Revista Espanola de Quimioterapia

 

Phase 3 trials of Tapinarof cream for plaque psoriasis.

16 Dec, 2021 | 08:49h | UTC

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis – New England Journal of Medicine

Commentary: Topical tapinarof reduces severity of plaque psoriasis – HealthDay

 

Commentary on Twitter

 

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

15 Dec, 2021 | 08:43h | UTC

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

News release: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

 

Commentaries on Twitter

 

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

15 Dec, 2021 | 08:46h | UTC

News release: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Commentaries:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Commentary on Twitter (thread – click for more)

 

[Not published yet] Initial data from South Africa showed vaccine protection vs. Omicron infection may drop to 30% but does cut severe disease.

15 Dec, 2021 | 08:38h | UTC

Vaccine protection vs. omicron infection may drop to 30% but does cut severe disease – NPR

See also: South Africa Omicron study finds drop in vaccine protection, fewer hospitalized – CIDRAP

 

M-A: Pharmacotherapy for adults with overweight and obesity – “phentermine–topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight”.

15 Dec, 2021 | 08:30h | UTC

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Infectious diseases learning pearls from inpatient ID consults.

15 Dec, 2021 | 08:22h | UTC

ID Learning Units from Inpatient ID Consults – HIV and ID Observations

 

Review | Anti-obesity drug discovery: advances and challenges.

14 Dec, 2021 | 08:49h | UTC

Anti-obesity drug discovery: advances and challenges – Nature Reviews Drug Discovery (free for a limited period – if the link is paywalled, try this one)

 

Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions.

14 Dec, 2021 | 08:44h | UTC

News release: Cannabis use could cause harmful drug interactions – Washington State University

Original Study: Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions – Drug Metabolism and Disposition

 

An observational study showed Moderna is associated with increased effectiveness vs. Pfizer vaccine against symptomatic SARS-CoV-2 infection.

13 Dec, 2021 | 09:52h | UTC

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection – Med

Related:

Opinion | Is Moderna really better than Pfizer—or is it just a higher dose?

CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

 

Commentary on Twitter

 

UK Report on SARS-CoV-2 variants of concern finds significantly lower vaccine effectiveness (VE) against Omicron infection, but a moderate to high VE of 70 to 75% is seen after a third (booster) dose.

13 Dec, 2021 | 09:53h | UTC

Report: SARS-CoV-2 variants of concern and variants under investigation in England – UK Health Security Agency

Commentaries:

Omicron: Three vaccine doses key for protection against variant – BBC

Two jabs offer little protection against Omicron infection, UK data shows – The Guardian

UK Says Omicron to Become Its Dominant Variant Within Days – Associated Press

 

Fauci says Omicron-specific version of Covid-19 vaccines may not be necessary.

13 Dec, 2021 | 09:51h | UTC

Fauci says Omicron-specific version of Covid-19 vaccines may not be necessary – STAT

 

Pooled analysis of randomized trials on the effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (EF) showed the effects were clinically meaningful and similar in patients with EF below 65% but were attenuated in patients with EF above 65%.

13 Dec, 2021 | 08:53h | UTC

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction – European Heart Journal

 

Commentary on Twitter

 

Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech vaccine had 90% effectiveness at preventing death due to Covid-19 compared to a two-dose regimen.

9 Dec, 2021 | 10:35h | UTC

BNT162b2 Vaccine Booster and Mortality Due to Covid-19 – New England Journal of Medicine

Editorial: Booster Doses and Prioritizing Lives Saved

 

Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech vaccine reduced the rates of confirmed Covid-19 and severe illness compared to a two-dose regimen.

9 Dec, 2021 | 10:32h | UTC

Protection against Covid-19 by BNT162b2 Booster across Age Groups – New England Journal of Medicine

Editorial: Booster Doses and Prioritizing Lives Saved

 

As 57 countries report Omicron cases, Pfizer says its boosters offer protection – but WHO cautions more research is needed.

9 Dec, 2021 | 10:28h | UTC

As 57 Countries Report Omicron Cases, Pfizer Says its Boosters Offer Protection – But WHO Cautions More Research is Needed – Health Policy Watch

See also: Covid: Vaccines should work against Omicron variant, WHO says – BBC

 

Multiple early studies find notable Omicron vaccine evasion.

9 Dec, 2021 | 10:26h | UTC

Multiple early studies find notable Omicron vaccine evasion – CIDRAP

Related: A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

 

RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.

9 Dec, 2021 | 10:21h | UTC

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine

Commentary: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center

 

Review: Current issues in the use of opioids for the management of postoperative pain.

9 Dec, 2021 | 10:18h | UTC

Current Issues in the Use of Opioids for the Management of Postoperative Pain: A Review – JAMA Surgery (free for a limited period)

 

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants.

8 Dec, 2021 | 10:22h | UTC

A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants – STAT

Original Study: SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection – medRxiv

 

Commentary from the author on Twitter (thread – click for more)

See also (thread – click for more)

 

Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule.

8 Dec, 2021 | 10:12h | UTC

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials – The Lancet Infectious Diseases

Invited Commentary: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases

 

Review: Perioperative pain management issues unique to older adults undergoing surgery.

8 Dec, 2021 | 09:52h | UTC

Perioperative Pain Management Issues Unique to Older Adults Undergoing Surgery: A Narrative Review – Annals of Surgery Open

 

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

7 Dec, 2021 | 10:19h | UTC

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults – Circulation

News Release: Young people recover quickly from rare myocarditis side effect of COVID-19 vaccine – American Heart Association

 

Study shows increased immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals.

7 Dec, 2021 | 10:21h | UTC

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals – JAMA

 

Commentary on Twitter (thread – click for more)

 

IDSA Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.

7 Dec, 2021 | 08:49h | UTC

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections – Clinical Infectious Diseases

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.